Technical Snapshots for These Medical Research Stocks -- VWR Corp., China Cord Blood, Laboratory Corp. of America, and Quest Diagnostics

Monday, October 2, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 2, 2017 /PRNewswire/ --

If you want a Stock Review on VWR, CO, LH, or DGX then come over to

and sign up for your free customized report. Pre-market today, monitors the most recent performance of four Medical Laboratories and Research equities, namely: VWR Corp. (NASDAQ: VWR), China Cord Blood Corp. (NYSE: CO), Laboratory
Corp. of America Holdings (NYSE: LH), and Quest Diagnostics Inc. (NYSE: DGX). The Medical Laboratories market includes independent, commercial enterprises that provide information to health care professionals about the severity, onset, and reason of patients' physical ailments. Access's complimentary reports for today's stocks line-up at:

VWR Corp. 

Radnor, Pennsylvania-based VWR Corp.'s stock finished last Friday's session 0.06% higher at $33.11. A total volume of 1.46 million shares was traded, which was above their three months average volume of 831,340 shares. The Company's shares have advanced 0.24% in the past month, 0.30% over the previous three months, and 32.28% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.21% and 10.32%, respectively. Additionally, shares of VWR Corp., which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have a Relative Strength Index (RSI) of 52.01.

On September 25th, 2017, VWR Corp. celebrated the opening of its new kitting center in Skalice, Czech Republic. The new facility will support the growing business of Therapak, which the Company acquired in 2016, by expanding its existing footprint in Europe with a state-of-the-art facility and comprehensive kitting services for regional and global customers. Visit us today and access your complete report on VWR for free at:

China Cord Blood 

On Friday, shares in Central, Hong Kong-based China Cord Blood Corp. ended the session 4.02% higher at $11.12. The stock recorded a trading volume of 294,695 shares. The Company's shares have gained 17.30% in the previous three months and 81.70% on an YTD basis. The stock is trading 33.60% above its 200-day moving average. Moreover, shares of the Company, which together with its subsidiaries, provides umbilical cord blood storage and ancillary services in China, have an RSI of 38.43.

On September 22nd, 2017, China Cord Blood announced that it will hold its 2017 annual general meeting of shareholders on December 07th, 2017 at 8:00 a.m. US EST at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong. Shareholders of record as of October 27th, 2017, will be entitled to receive notice of and vote at the annual general meeting. The complimentary research report on CO can be accessed at:

Laboratory Corp. of America 

Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' (LabCorp®) shares gained 0.81%, closing the session at $150.97 with a total trading volume of 476,457 shares. The stock has gained 17.60% on an YTD basis. The stock is trading 4.77% above their 200-day moving average. Additionally, shares of LabCorp®, which operates as an independent clinical laboratory company worldwide, have an RSI of 38.87.

On September 07th, 2017, LabCorp® has been named to Forbes' 2017 ranking of "The World's Most Innovative Companies." Companies on the list are ranked by an "innovation premium" tied to market cap, cash flows, and investors' expectations of "profitable new growth". Register for free on and download the research report on LH at:

Quest Diagnostics 

Last Friday at the close, shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 2.45 million shares, which was above their three months average volume of 964,630 shares. The stock ended the session 1.83% higher at $93.64. The Company's shares have advanced 1.89% since the start of this year. The stock is trading below its 200-day moving average by 8.03%. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 21.26.  

On September 25th, 2017, research firm Raymond James downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.

On September 28th, 2017, Quest Diagnostics announced that it will report Q3 2017 results on October 19th, 2017, before the market opens. The Company will hold its quarterly conference call beginning at 8:30 a.m. ET on that day to discuss the results.  Get free access to your research report on DGX at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store